Key result
Alpha One International Registry outlines key epidemiology, genetics, biochemistry, and therapeutic options for deficiency.
Why the study?
Alpha1-antitrypsin deficiency is a rare and often under-recognised condition requiring improved understanding and awareness through standardized multinational data collection.
This meeting report summarizes the 2nd Alpha One International Registry meeting, providing an update on alpha1-antitrypsin deficiency to improve understanding and awareness.
Updates AATD knowledge for clinicians; leaves open prospective validation of novel therapies.
The Alpha One International Registry is a scientific foundation established to comply with a World Health Organization recommendation to develop a multinational registry of alpha1-antitrypsin deficiency, with the aim of creating a common database of subjects recognised in a standardised way. A commitment of the Alpha One International Registry members, belonging to 15 national registries, is to meet every 2 yrs in an open scientific conference to provide a scientific and clinical update on the deficiency. The second Alpha One International Registry meeting was held in Rapallo (Genoa, Italy) on September 27th-28th, 2001, and 26 speakers provided an exhaustive overview of all aspects of alpha1-antitrypsin deficiency, including epidemiology, genetics, biochemistry, associated conditions, established and novel therapeutic options, and markers of efficacy. In the framework of a rare and often under-recognised condition, this meeting is likely to be central to improving understanding and increasing awareness of alpha1-antitrypsin deficiency.
No takes yet. Share an insight, caveat, or question.
Luisetti et al. (2002) studied alpha1-antitrypsin deficiency. The second Alpha One International Registry meeting provided an exhaustive overview of epidemiology, genetics, biochemistry, and therapeutic options for alpha1-antitrypsin deficiency.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: